SCHEMBL10242698

SCHEMBL10242698

CC(=O)Cn1ccc2cccc(Cl)c21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.47
ADRA2A P08913 1/20 0.44
ADRA2B P18089 1/20 0.44
ADRA2C P18825 1/20 0.44
HRH3 Q9Y5N1 1/20 0.41
BACE1 P56817 1/20 0.41
KMT2A Q03164 2/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
FFAR4 Q5NUL3 1/20 0.37
NOTUM Q6P988 1/20 0.37
MAPK1 P28482 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 2/20 0.35
LMNA P02545 1/20 0.35
ITGB2 P05107 1/20 0.35
ICAM1 P05362 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1576332 0.85 KMT2A (0.56) NPY5RADRA2AADRA2BADRA2CHRH3
SCHEMBL10203770 0.84 NPY5R (0.45) NPY5RADRA2AADRA2BADRA2CHRH3
SCHEMBL2012127 0.84 NPY5R (0.44) NPY5RADRA2AADRA2BADRA2CHRH3
SCHEMBL10165372 0.83 NPY5R (0.44) NPY5RADRA2AADRA2BADRA2CHRH3
SCHEMBL16234652 0.82 ADRA2A (0.45) ADRA2AADRA2BADRA2CKMT2ANOTUM
SCHEMBL20037307 0.81 HTT (0.46) NPY5RBACE1KMT2AKDM4EL3MBTL1
SCHEMBL13139572 0.81 KMT2A (0.39) NPY5RKMT2ACYP1A2CYP3A4CYP2C19
SCHEMBL10203092 0.81 FABP4 (0.41) KMT2ANOTUMMAPK1LMNASLC6A2
SCHEMBL14473516 0.78 ADRA2A (0.49) NPY5RADRA2AADRA2BADRA2CHRH3
SCHEMBL1576304 0.76 KMO (0.52) NPY5RADRA2AADRA2BADRA2CHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148373-B2 Compounds ASTRAZENECA AB (SE) 2012-04-03 US disclosed
US-20090298807-A1 Compounds ASTRAZENECA AB (SE) 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298807-A1 Compounds PKD1, SLC10A1, ABCB11 NPY5R 1030/4885ADRA2A 226/4885ADRA2B 246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.